<DOC>
	<DOCNO>NCT02338349</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability preliminary efficacy RAD1901 patient advance ER+ , HER2-negative breast cancer .</brief_summary>
	<brief_title>A Phase I , Multicenter , Open-Label , Multi-Part , Dose-escalation Study RAD1901 Postmenopausal Women With Advanced Estrogen Receptor Positive HER2-Negative Breast Cancer</brief_title>
	<detailed_description>The primary objective determine maximum tolerate dose ( MTD ) and/or recommend Phase 2 dose ( RP2D ) RAD1901 patient advance ER+HER2-negative breast cancer . The secondary objective study : - To assess safety tolerability RAD1901 - To evaluate pharmacokinetics ( PK ) RAD1901 - To evaluate preliminary anti-tumor effect RAD1901</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>1 . Patients must postmenopausal woman , define protocol 2 . 18 year old 3 . Patients histological cytological proven diagnosis adenocarcinoma breast evidence either locally advance , inoperable and/or metastatic disease 4 . Patients must receive 2 prior chemotherapeutic regimen least 6 month prior endocrine therapy 1 . Prior anticancer investigational drug treatment within follow window : 1 . Tamoxifen therapy le 14 day first dose study treatment 2 . Fulvestrant therapy le 90 day first dose study treatment 3 . Any anticancer endocrine therapy le 14 day first dose study treatment 4 . Any chemotherapy le 28 day first dose study 5 . Any investigational drug therapy le 28 day 3 halflives ( whichever longer ) prior first dose study treatment 2 . Patients untreated symptomatic central nervous system ( CNS ) metastases 3 . Patients endometrial disorder , include evidence endometrial hyperplasia , dysfunctional uterine bleeding cyst</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>